AptaBio Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 1.57%

AptaBio Therapeutics Inc (293780) has an Asset Resilience Ratio of 1.57% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 293780 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

₩1.05 Billion

≈ $712.80K USD Cash + Short-term Investments

Total Assets

₩67.12 Billion

≈ $45.49 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how AptaBio Therapeutics Inc's Asset Resilience Ratio has changed over time. See 293780 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down AptaBio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AptaBio Therapeutics Inc (293780) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.05 Billion	1.57%
Total Liquid Assets	₩1.05 Billion	1.57%

Asset Resilience Insights

Limited Liquidity: AptaBio Therapeutics Inc maintains only 1.57% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

AptaBio Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare AptaBio Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	1.96%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	8.47%

Annual Asset Resilience Ratio for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual Asset Resilience Ratio data for AptaBio Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	7.71%	₩5.97 Billion ≈ $4.05 Million	₩77.43 Billion ≈ $52.48 Million	-22.41pp
2023-12-31	30.12%	₩27.87 Billion ≈ $18.89 Million	₩92.52 Billion ≈ $62.70 Million	+3.34pp
2022-12-31	26.78%	₩15.03 Billion ≈ $10.18 Million	₩56.11 Billion ≈ $38.03 Million	-8.52pp
2021-12-31	35.30%	₩22.91 Billion ≈ $15.53 Million	₩64.91 Billion ≈ $43.99 Million	-21.47pp
2020-12-31	56.76%	₩42.82 Billion ≈ $29.02 Million	₩75.44 Billion ≈ $51.13 Million	-2.87pp
2019-12-31	59.63%	₩46.16 Billion ≈ $31.28 Million	₩77.40 Billion ≈ $52.46 Million	-37.25pp
2018-12-31	96.88%	₩19.69 Billion ≈ $13.35 Million	₩20.33 Billion ≈ $13.78 Million	+0.80pp
2017-12-31	96.08%	₩10.57 Billion ≈ $7.16 Million	₩11.00 Billion ≈ $7.46 Million	--

pp = percentage points

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$154.30 Million

₩227.69 Billion KRW

Market Cap Rank

#17532 Global

#822 in Korea

Share Price

₩8470.00

Change (1 day)

+1.80%

52-Week Range

₩6110.00 - ₩10440.00

All Time High

₩61500.00